Zacks Investment Research lowered shares of Syros Pharmaceuticals Inc. (NASDAQ:SYRS) from a hold rating to a sell rating in a research report report published on Thursday morning.

According to Zacks, “Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company’s product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “

Other equities research analysts have also issued research reports about the company. Piper Jaffray Cos. reissued a buy rating and set a $20.00 price objective on shares of Syros Pharmaceuticals in a research note on Thursday, September 22nd. JMP Securities started coverage on Syros Pharmaceuticals in a research note on Monday, July 25th. They set an outperform rating and a $22.00 price objective for the company. Wedbush started coverage on Syros Pharmaceuticals in a research report on Monday, July 25th. They set an outperform rating and a $18.00 price target on the stock. Cowen and Company started coverage on Syros Pharmaceuticals in a research report on Monday, July 25th. They set an outperform rating on the stock. Finally, HC Wainwright restated a hold rating and set a $10.00 price target on shares of Syros Pharmaceuticals in a research report on Friday, September 9th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of Buy and an average price target of $17.50.

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

Shares of Syros Pharmaceuticals (NASDAQ:SYRS) traded up 0.70% during trading on Thursday, reaching $12.91. The company’s stock had a trading volume of 356 shares. Syros Pharmaceuticals has a 12-month low of $8.16 and a 12-month high of $21.50. The stock’s market cap is $301.76 million. The stock’s 50-day moving average is $13.57 and its 200-day moving average is $13.04.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings data on Monday, November 14th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.54) by $0.11. Equities research analysts anticipate that Syros Pharmaceuticals will post ($2.98) earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SYRS. California State Teachers Retirement System bought a new position in Syros Pharmaceuticals during the third quarter valued at approximately $137,000. Spark Investment Management LLC bought a new position in Syros Pharmaceuticals during the third quarter valued at approximately $160,000. Hamilton Lane Advisors LLC bought a new position in Syros Pharmaceuticals during the third quarter valued at approximately $193,000. Morgan Stanley bought a new position in Syros Pharmaceuticals during the third quarter valued at approximately $469,000. Finally, AWM Investment Company Inc. bought a new position in Syros Pharmaceuticals during the third quarter valued at approximately $660,000. Hedge funds and other institutional investors own 54.63% of the company’s stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing treatments for cancer and immune-mediated diseases. The Company’s gene control platform focuses on identifying gene control targets linked to genomically defined patient populations, and drugging gene control targets.

5 Day Chart for NASDAQ:SYRS

Receive News & Stock Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.